ImmunityBio, Inc. (IBRX)
Largest Insider Buys in Sector
IBRX Stock Price History Chart
IBRX Stock Performance
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as …
Insider Activity of ImmunityBio, Inc.
Over the last 12 months, insiders at ImmunityBio, Inc. have bought $0 and sold $0 worth of ImmunityBio, Inc. stock.
On average, over the past 5 years, insiders at ImmunityBio, Inc. have bought $15.1M and sold $8.41M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 71,915 shares for transaction amount of $198,023 was made by BLASZYK MICHAEL D (director) on 2023‑06‑05.
List of Insider Buy and Sell Transactions, ImmunityBio, Inc.
| 2023-06-05 | director | 71,915 0.0166% | $2.75 | $198,023 | +30.82% | |||
| 2023-06-02 | director | 25,000 0.006% | $2.83 | $70,700 | +31.59% | |||
| 2023-06-02 | director | 15,000 0.0035% | $2.78 | $41,700 | +31.59% | |||
| 2023-06-01 | director | 7,000 0.0016% | $2.91 | $20,370 | +23.81% | |||
| 2021-10-08 | CEO & President | 1,930 0.0005% | $8.81 | $16,995 | -38.25% | |||
| 2021-08-23 | Sale | director | 14,801 0.0035% | $10.12 | $149,795 | -45.86% | ||
| 2021-08-20 | Sale | director | 9,976 0.0025% | $10.00 | $99,808 | -41.00% | ||
| 2021-08-18 | Sale | director | 2,133 0.0006% | $10.03 | $21,389 | -36.74% | ||
| 2021-08-17 | Sale | director | 43,398 0.0112% | $10.12 | $439,361 | -41.04% | ||
| 2021-05-25 | Sale | director | 88,787 0.0237% | $16.18 | $1.44M | -54.64% | ||
| 2021-05-24 | Sale | director | 21,223 0.0056% | $16.02 | $340,071 | -54.46% | ||
| 2021-05-21 | Sale | director | 14,990 0.0039% | $16.09 | $241,164 | -53.43% | ||
| 2021-02-05 | Sale | See remarks | 22,100 0.0056% | $23.09 | $510,267 | -52.76% | ||
| 2021-02-02 | Sale | See remarks | 82,070 0.0212% | $20.65 | $1.69M | -46.10% | ||
| 2021-01-28 | Sale | See remarks | 11,304 0.0033% | $20.53 | $232,121 | -39.34% | ||
| 2021-01-27 | Sale | See remarks | 36,626 0.01% | $20.61 | $754,946 | -42.76% | ||
| 2021-01-12 | Sale | Chief Financial Officer | 16,364 0.004% | $15.00 | $245,460 | -26.52% | ||
| 2021-01-04 | Sale | Chief Financial Officer | 39,271 0.0102% | $13.62 | $534,938 | -6.48% | ||
| 2020-12-22 | Sale | See remarks | 130,000 0.1231% | $18.05 | $2.35M | -22.23% | ||
| 2020-12-10 | Sale | director | 42,592 0.0385% | $10.83 | $461,122 | +25.09% |
Insider Historical Profitability
| SOON-SHIONG PATRICK | Chairman and CEO | 23750750 3.2528% | $2.69 | 2 | 0 | <0.0001% |
| BLASZYK MICHAEL D | director | 71915 0.0098% | $2.69 | 1 | 0 | +30.82% |
| Brennan John Owen | director | 15000 0.0021% | $2.69 | 2 | 0 | +31.59% |
| Clark Wesley | director | 8000 0.0011% | $2.69 | 1 | 0 | +23.81% |
| Wilson Angela | Chief Financial Officer | 3265 0.0004% | $2.69 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| State Street | $76.17M | 2.05 | 14.18M | +49.77% | +$25.31M | <0.01 | |
| The Vanguard Group | $72.71M | 1.96 | 13.54M | +1.58% | +$1.13M | <0.01 | |
| BlackRock | $55.72M | 1.5 | 10.38M | -3.13% | -$1.8M | <0.01 | |
| Geode Capital Management | $18.7M | 0.5 | 3.48M | +3.02% | +$547,396.77 | <0.01 | |
| Credit Suisse | $8.32M | 0.22 | 1.55M | +1.24% | +$101,589.66 | 0.01 |